InvestmentJul 1, 2026, 08:57 AM
Abivax Shares Resume Trading on Euronext Paris After Offering Halt
AI Summary
Abivax S.A. announced the resumption of trading of its ordinary shares on Euronext Paris as of 3:30 p.m. CEST on July 1, 2026. The trading had been halted earlier the same day at the company's request. This halt was implemented to facilitate the confirmation of investor allocations and the announcement of the pricing for its previously disclosed public offering of American Depositary Shares in the United States.
Key Highlights
- Abivax ordinary shares resumed trading on Euronext Paris at 3:30 p.m. CEST on July 1, 2026.
- Trading was halted at the company's request from 9:00 a.m. CEST on July 1, 2026.
- The halt was in connection with a previously announced public offering of American Depositary Shares (ADS) in the United States.
- The purpose of the halt was to confirm investor allocations and announce the pricing of the offering.
- Abivax is a clinical-stage biotechnology company focused on chronic inflammatory diseases.
- Its lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for ulcerative colitis.
Price Impact
More from ABVX